Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Change in Receivables (2016 - 2026)

Tandem Diabetes Care filings provide 13 years of Change in Receivables readings, the most recent being $42.0 million for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 247.71% to $42.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $56.8 million, a 173.2% increase, with the full-year FY2025 number at $56.8 million, up 173.2% from a year prior.
  • Change in Receivables hit $42.0 million in Q4 2025 for Tandem Diabetes Care, up from $1.3 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $42.0 million in Q4 2025 to a low of -$22.8 million in Q1 2023.
  • Median Change in Receivables over the past 5 years was $7.1 million (2021), compared with a mean of $5.6 million.
  • Biggest five-year swings in Change in Receivables: tumbled 201.17% in 2021 and later surged 247.71% in 2025.
  • Tandem Diabetes Care's Change in Receivables stood at $24.2 million in 2021, then crashed by 87.47% to $3.0 million in 2022, then skyrocketed by 84.41% to $5.6 million in 2023, then surged by 115.96% to $12.1 million in 2024, then surged by 247.71% to $42.0 million in 2025.
  • The last three reported values for Change in Receivables were $42.0 million (Q4 2025), $1.3 million (Q3 2025), and $2.7 million (Q2 2025) per Business Quant data.